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Abstract
Background: Inhibitor of differentiation protein 4 (ID4) is a dominant negative regulator of the basic helix-loop-
helix (bHLH) family of transcription factors. During tumorigenesis, ID4 may act as a tumor suppressor or as an
oncogene in different tumor types. However, the role of ID4 in breast cancer is not clear where both an oncogenic
and a tumor suppressor function have been attributed. Here, we hypothesize that ID4 behaves as both, but its role
in breast differs according to the estrogen receptor (ER) status of the tumor.
Methods: ID4 expression was retrieved from TCGA database using UCSC Xena. Association between overall survival
(OS) and ID4 was assessed using Kaplan–Meier plotter. Correlation between methylation and expression was
analyzed using the MEXPRESS tool. In vitro experiments involved ectopic expression of ID4 in MCF-7, T47D, and
MDA-MB231 breast cancer cell lines. Migration and colony formation capacity were assessed after transfection
treatments. Gene expression was analyzed by ddPCR and methylation by MSP, MS-MLPA, or ddMSP.
Results: Data mining analysis revealed that ID4 expression is significantly lower in ER+ tumors with respect to
ER− tumors or normal tissue. We also demonstrate that ID4 is significantly methylated in ER+ tumors. Kaplan–Meier
analysis indicated that low ID4 expression levels were associated with poor overall survival in patients with
ER+ tumors. In silico expression analysis indicated that ID4 was associated with the expression of key genes of the
ER pathway only in ER+ tumors. In vitro experiments revealed that ID4 overexpression in ER+ cell lines resulted in
decreased migration capacity and reduced number of colonies. ID4 overexpression induced a reduction in ER levels
in ER+ cell lines, while estrogen deprivation with fulvestrant did not induce changes neither in ID4 methylation nor
in ID4 expression.
Conclusions: We propose that ID4 is frequently silenced by promoter methylation in ER+ breast cancers and
functions as a tumor suppressor gene in these tumors, probably due to its interaction with key genes of the ER
pathway. Our present study contributes to the knowledge of the role of ID4 in breast cancer.
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Background
Inhibitor of differentiation (ID) proteins 1, 2, 3, and 4
regulate the expression of genes by acting as dominant
negative regulators of the basic helix-loop-helix (bHLH)
transcription factors. ID proteins interact with the bHLH
transcription factors and form heterodimers, inhibiting
in this way their possible binding to DNA since ID pro-
teins lack the basic DNA-binding domain [1]. During
differentiation, the expression of ID proteins is downreg-
ulated in cells, and on the contrary, it is increased in
stem cells [2]. In human tumors, an increased expression
of ID proteins has been associated with reversion to an
embryonic-like state, with loss of differentiation, in-
creased migration, proliferation, and neo-angiogenesis
[3]. However, discordant literature attributes opposite
roles to ID proteins; for example, some studies have also
recognized ID proteins as critical actors of antiprolifera-
tive signaling pathways in cancer [4]. So, it seems then
that, according to the cellular context, ID proteins can
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pursue divergent functions and act as oncoproteins or
tumor suppressors [2].
ID4 is a member of this protein family and it has been
shown to be highly expressed in neurons [5], osteoblasts
[6], adipocytes [7], prostate epithelial cells [8], and testicu-
lar Sertoli cells [9]. In embryogenesis, ID4 is required for
normal mammary [10] and prostate gland development
[8]. In cancer, ID4 presents again divergent roles since it
has been described to act as a tumor suppressor in pros-
tate [11], lung [12], and gastric [13] tumors, and as an
oncogene in ovarian cancer [14] and glioblastomas [15].
In breast cancer, the role of ID4 is not clear. Epigenetic
silencing of ID4 (a characteristic mechanism to downregu-
late tumor suppressor genes during cancer progression)
has been described in mammary columnar cell lesions,
ductal carcinoma in situ, and invasive carcinomas [16]. In
addition, the hypermethylation of ID4 promoter has been
associated with an increased risk of lymph node metastasis
[17]. Epigenetic silencing and gene expression downregu-
lation are hallmarks of tumor suppressor gene function,
since their absence allows the progress of a tumorigenic
process. However, we and others have found the opposite
role for ID4 in breast tumors. Increased ID4 expression
has been informed in basal cell-like breast cancer [18],
and we found increased expression and hypomethylation
of its promoter in triple-negative breast cancer (TNBC)
[19]. Moreover, increased ID4 expression has been associ-
ated with the ability of breast cancer cells to exhibit
anchorage-independent growth [20]. Also, high ID4 ex-
pression in TNBC has been associated with BRCA1 down
regulation and BRCAness phenotype [21, 22]. Therefore,
enough evidence exists to conclude that ID4 can assume
distinct roles in breast cancer, depending on the cellular
context. We hypothesize that ID4 acts as both, tumor sup-
pressor and oncogene, but its role will differ according to
the ER status of the breast cancer cell. We have previously
demonstrated that ID4 acts as an oncogene in ER-negative
tumors. In this work, we hypothesize that ID4 may behave
as a tumor suppressor in an ER+ cellular context.
Methods
Cell lines and cell culture
Human breast cancer cell lines MCF-7, T47D, and
MDA-MB231, were kindly provided by Dr. Lanari from
the IBYME Institute, Buenos Aires, Argentina and by
Dr. Matias Sanchez, IMBECU Institute, Mendoza,
Argentina, respectively. Cell lines were cultured in DMEM
medium (Gibco by Life Technologies, Grand Island, NY,
USA, # 1852779) supplemented with 10% fetal bovine
serum (Internegocios S.A, Mercedes, BA, Argentina),
100 U/mL of penicillin, and 100 μg/mL streptomycin
(Gibco by Life Technologies, Grand Island, NY, USA,
#1796440). All cell lines were incubated at 37 °C in a hu-
midified atmosphere containing 5% CO2. For estrogen
depletion experiments, cells were cultured in phenol
red-free RPMI supplemented with charcoal-stripped 10%
fetal bovine serum for 1 week prior to drug treatment.
After this time, fulvestrant 1 μM was added to the
medium and cells were treated for 72 h.
Plasmids and transfections
The full-length human ID4 cloned into pCMV vector
(pCMV-Id4) was a generous gift from Dr. Mark Israel.
Transfection of 3 μg of pCMV-ID4 or 3 μg pGFP (as con-
trol vector) were performed with Lipofectamine 2000
(Invitrogen, Van Allen Way Carlsbad, CA, USA # 1828126)
at 90% confluence according to the manufacturer’s instruc-
tions. Transfection was monitored by fluorescence micros-
copy and after 48 h, it achieved a 70% efficiency. ID4
overexpression was confirmed by Western blot
(Additional file 1: Figure S1). After transfection, different
assays were performed as described below.
Migration assay
Forty-eight hours after transfection, the migration assay
was started. Cells were serum-starved overnight before
the scratch was produced; afterwards, the cells were
maintained in a serum-reduced medium containing 0.5%
FBS. Cell cultures were then scratched with a 200 μL
sterile pipette tip and extensively washed with PBS to re-
move detached cells and debris. One cross was scratched
in each well; then, images of the same area were taken at
24, 48, and 72 h. These were instantly center-imaged at
× 4 magnification, using a T-2000 microscope equipment
(Nikon, Tokyo, Japan).
Colony formation assay
After transfection, MCF7 and T47D cells were platted at
a density of 1000 cells per well in six well plates and
allowed to adhere overnight at 37 °C, 5% CO2. The cells
were allowed to grow until control treatment colonies
reached > 50 cells per colony (approximately 12 days).
Colonies were then fixed with glutaraldehyde for
30 min, stained with crystal violet 0.5% for 30 min and
washed. Next, colony number was counted by using an
automatized procedure with Image J software.
Methylation analysis
For MSP and droplet digital MSP (ddMSP) assays,
DNA was firstly bisulfite-converted with the EZ DNA
Methylation-Direct ™ Kit (Zymo RESEARCH, Irvine,
California, USA). Primers used for MSP and ddMSP
were specific for detection of the methylated and
un-methylated status of the ID4 promoter. Primers were
purchased from Integrated DNA Technologies (CA,
USA). Forward primers for MSP covered the TATA box,
E-box, and three CpG sites in the minimal promoter re-
gion (− 48 to + 32) [23]. The methylation-specific primer
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set was as follows: forward, 5′-TTTTATAAATATAG
TTGCGCGGC-3′; and reverse, 5′-GAAACTCCG
ACTAAACCCGAT-3′. The unmethylation-specific pri-
mer set was as follows: forward, 5′-TTT
TATAAATATAGTTGTGTGGTGG-3′; and reverse,
5′-TCA AAACTCCAACTAAACCCAAT-3′. The PCR
amplification reaction for MSP was performed in a
25 μl final volume and consisted of a 40-cycle program,
composed of 30s at 94 °C, 30 s at 58 °C, and 30 s at 72 °C,
followed by a 7 min final extension at 72 °C. Mg2+ concen-
tration was 1.5 mM for methylated-specific and 2.5 mM
for unmethylated-specific primer sets. Primer concen-
tration was 0.1 μM for methylated-specific and
0.4 μM for unmethylated-specific primer sets. PCR
products were resolved by 2% agarose gel electrophor-
esis and quantified by ImageJ software. ddPCR gen-
eral specifications are described below.
The MS-MLPA assays were performed basically accord-
ing to manufacturer’s recommendations (MRC-Holland,
Amsterdam, The Netherlands, (www.mlpa.com). A CpG
site was considered to be methylated when the methyla-
tion dosage ratio between digested and undigested sample
was superior to the cut-off threshold of 8% [19].
Droplet digital PCR
Purified RNA was converted to cDNA using M-MLV
Reverse Transcriptase, and cDNA was diluted to 0.2 ng/μl
and stored at − 20 °C until use. For each assay, 5 μl of the
diluted sample (1 ng cDNA) was run using the Bio-Rad
EvaGreen master mix. For each assay, droplets were gen-
erated using Droplet Generation Oil for EvaGreen
(Bio-Rad) on the QX200 Droplet Generator (Bio-Rad)
according to the manufacture’s protocol and adding the
specific primers for ER with the following sequence:
forward, 5′-CAGGACTCGGTGGATATGGT; and re-
verse, 5′-CCAGGGAAGCTACTGTTTGC. Droplets
were cycled on the C1000 Touch Thermal Cycler
(Bio-Rad) for 40 cycles, with a 58 °C annealing
temperature. Droplets were read using the QX200
Droplet Reader (Bio-Rad). Data was analyzed in Quan-
taSoft software (Bio-Rad). Each DNA sample was run
in three technical replicates and the mean was consid-
ered for further comparisons.
In silico data analysis
TCGA breast cancer data was obtained from the UCSC
Xena resource (http://xena.ucsc.edu/). For gene expres-
sion, the RNA-Seq (polyA+ Illumina HiSeq) data was
downloaded as log2 (norm_count+ 1) values. For methy-
lation analysis, the Illumina Infinium Human Methyla-
tion 450 platform was retrieved. This platform
represents DNA methylation as beta values, which are
continuous variables between 0 and 1, representing the
ratio of the intensity of the methylated bead type to the
combined locus intensity.
Additionally, the MEXPRESS tool was used for
visualization and interpretation of the expression,
methylation, and clinical data available in TCGA
(http://mexpress.be/) [24]. Survival curves were esti-
mated using the Kaplan–Meier plotter tool (http://
kmplot.com/analysis/). This tool uses an online data-
base of published microarray datasets for breast, ovar-
ian, lung, and gastric cancer, and it includes clinical
and gene expression data for 5143 breast cancer pa-
tients [25]. The analyses were performed using the Jet-
Set best probe set. Survival was also analyzed using the
breast cancer Miller cohort downloaded form (http://
xena.ucsc.edu/) [26].
The association between relative gene expression
values was performed by SVD (singular-value decompos-
ition) as previously described [22]. The correlation coef-
ficients between ID4 and each specific gene were
calculated by the standard statistical procedure described
by Wonnacott and Wonnacot (Introductory Statistics,
2nd ed., John Wiley, 1972, pp. 326–331). These statis-
tical analyses were performed using MATLAB (Natick,
MA, USA). mRNA expression differences between
groups of breast cancers were assessed using unpaired
Student’s t test and a one-way analysis of variance with
Bonferroni’s post hoc analysis for comparison between
multiple groups.
ArrayExpress data
For ID4 expression analysis in MCF-7 control vs.
fulvestrant-treated cells, an in vitro model of MCF-7
cells treated with ER antagonists was retrieved from
ArrayExpress with the accession number E-MTAB-4426.
The intensity of ID4 probe (A_23_P59375) was com-
pared between the following conditions: WT_CCS+ Fulv
vs. WT_CCS + DMSO [27].
Additional statistical analysis
Unless otherwise noted, all laboratory experiments were
realized a minimum of three separate times and statis-
tical analysis were performed using Graph Pad Prism
software version 5. A Student’s t test was used for com-
parison between two groups. Significance was defined as
a p value < 0.05.
Results
In silico analyses reveal that ID4 expression differs
according to ER status in breast cancer
We first aimed to study the expression of ID4 across
breast tumors with different ER status. For this, we used
the IlluminaHiSeq_RNASeqV2 expression data from 780
breast tumors and 138 normal breast tissue samples from
the TCGA (The Cancer Genome Atlas) database. We
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divided the tumor samples in two groups: ER+ (n = 601)
and ER− (n = 179). As shown in Fig. 1a, ER+ breast tu-
mors present a significant reduction in ID4 expres-
sion as compared to ER− tumors and to normal
tissue (p < 0.001). Next, we performed a new analysis
but, in this case, considering ID4 expression accord-
ing to the PAM50 breast cancer molecular classifica-
tion, i.e., luminal A, luminal B, normal-like, basal-like,
and HER2-enriched. As shown in Fig. 1b, ID4
expression is significantly lower in luminal A (n = 434)
and luminal B (n = 194) subtypes (both ER+) as com-
pared with basal-like (n = 142) and normal-like breast
tumors (n = 119) (both ER−) (p < 0.001). HER2-enriched
subtype (n = 66) showed significantly lower levels of ID4
expression with respect to basal-like or normal-like tu-
mors (p < 0.001). This observation could be confusing
given that this subtype is often thought of as being ER−
only. However, it should be taken into consideration that
b
a
Fig. 1 Comparison of ID4 expression among different breast cancer subtypes. a–b The expression of ID4 is shown relative to a ER+ (n = 601) and
ER− (n = 179) and normal tissue (n = 114), b PAM50 molecular subtypes: luminal a (n = 434), luminal b (n = 194), basal-like (n = 142), normal-like
breast tumors (n = 119), and HER2-enriched (n = 66). The Student’s t test was applied to evaluate differences in ID4 expression between two
groups and one way analysis of variance (ANOVA) with Bonferroni’s post hoc analysis to compare three or more groups. The bottom and top of
the box represent the first and third quartiles of the data, respectively, and the band inside the box represents the median of the data. The lower
and upper whiskers represent the lowest and highest data points of the data, respectively. As can be seen in panel a and b, ID4 expression is
reduced in ER+ subgroups ***p < 0.001
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the HER2-enriched subtype can include ER+ and ER− tu-
mors as well. This mixed composition could explain lower
levels of ID4 expression for this subtype.
Taken together, our results show that ID4 expression
differs according to the ER status, and that its expression
is significantly lower in ER+ breast tumors.
High ID4 expression is associated with better prognosis
in ER+ breast tumors
To evaluate whether the expression level of ID4 could
have any predictive value for breast cancer overall sur-
vival (OS), we used the online survival analysis software,
Kaplan–Meier (KM) plotter [25]. This tool allowed us to
study the expression of ID4 as dichotomized values in
“high” or “low” according to the median expression of
the gene. The relationship between ID4 expression and
OS of 799 breast cancer patients was analyzed separating
ER+ (n = 548) from ER− (n = 251) cases. As shown in
Fig. 2a, among the patients with ER+ tumors, those with
higher ID4 expression levels presented better probabil-
ities of survival (p < 0.001); this result suggests that this
group of patients with high ID4 expression levels
have an active (not silenced) ID4 tumor suppressor
gene. Remarkably this was not observed in ER− tu-
mors (Fig. 2b) (p = 0,49). To confirm these results, we
performed a Kaplan–Meier analysis using another
database such as the Miller 2005 cohort. We analyzed
OS in 213 ER+ breast cancer patients dividing ID4
values in high or low according to the median expres-
sion of the gene. As shown in Additional file 2:
Figure S2 higher ID4 expression levels were associ-
ated with better probabilities of survival in line with
Kaplan–Meier plotter results. Given that high ID4
expression was only beneficial in the ER+ group, we
speculate that ID4 has a tumor suppressor role in
these tumors.
ID4 expression is downregulated through methylation in
ER+ breast tumors as assed by in silico analyses
Since ID4 expression has been shown to be principally
regulated trough methylation [13, 17, 28], we asked if
there are differences in the methylation levels of ID4 ac-
cording to the ER status. To answer this question, we
queried the MEXPRESS tool which allows the
visualization and interpretation of the gene expression,
the methylation and the clinical data available in TCGA
[24]. As shown in Fig. 3, this tool permitted us to
analyze the methylation of ID4 tested with 13 probes
distributed in different regions of the gene (the
localization of each probe is represented in the figure
and the ones localized in the promoter region are
highlighted in dark blue). As can be observed, the
methylation values increase as tumors become ER+; this
can also be observed in Additional file 3: Figure S3 for
CpGs in the promoter of ID4. All the regions analyzed
presented a negative correlation with respect to ID4
gene expression (Pearson’s correlation coefficients for
each probe are indicated on the right), suggesting that
ID4 methylation silences gene expression.
Another interesting observation is that ER status and
ID4 expression present an inverse correlation, where ID4
expression gradually diminishes (due to promoter methy-
lation) as tumors become ER+ (p < 0.0001). The MEX-
PRESS tool also allowed us to visualize ID4 expression
and methylation status according to PAM50 breast cancer
molecular classification. As observed in Fig. 3 the methy-
lation of ID4 increases (and ID4 expression decreases) in
Fig. 2 Kaplan–Meier survival curves indicate a better survival for high ID4 expression in patients with ER+ tumors. a–b Overall survival curves
calculated by KM plotter, for patients with tumors classified as ER+ (a) and ER− (b) respectively. Survival probability is represented on the y-axis,
time (in months) on the x-axis. Black curve corresponds to low ID4 expression, and red curves to high ID4 expression. As can be noticed, only in
a ER+ context the enhanced expression of ID4 contributes to a difference in OS (panel a)
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luminal A and luminal B subtypes (both ER+ and repre-
sented as green lines in Fig. 3) whereas methylation de-
creases (and expression increases) in basal-like and
normal-like subtypes (both ER− and represented in
Fig. 3 as yellow and blue lines respectively). Since aber-
rant DNA methylation of promoter regions is one of
the mechanisms for the silencing of tumor suppressor
genes in cancer, and because ID4 promoter is mostly
methylated in ER+ tumors, we can again speculate that
ID4 behaves principally as a tumor suppressor gene in
these groups of breast tumors.
ID4 expression is associated to the expression of different
genes according to ER status
We next expanded our analysis to investigate whether
the expression of ID4 is associated with different genes
according to the ER status. To test this, we used the
singular-value decomposition (SVD) analysis and studied
the expression of ID4 vs. the expression of 66 genes with
different functions in breast cancer (Table 1) in 780 sam-
ples from TCGA database. SVD represents an appropri-
ate tool for gene expression analysis in which the
singular values are associated with the importance of
each variable in the linear system. The SVD program we
used for this analysis is not a commercial one, such as
MATHLAB, because these programs sort the singular
values after they are calculated, and as a consequence,
one loses the correspondence between ID4 and the gene
under study. Rather, we used a C++ program written by
one of the authors that leaves the singular values un-
sorted and hence maintains this correspondence. To de-
fine the most relevant genes associated with ID4
expression, we selected the genes that were higher than
the median for the 66 singular values; 15 of the 66 genes
met this criterion, which differed depending on the ER
status. In ER+ tumors, ID4 expression was associated
with the expressions of FOXA1, GATA3, ESR1, CCND1,
AKT1, and IGFR; whereas in ER− tumors, ID4 expres-
sion was associated with VEGF, JUN, and MKI67.
Finally, shared association was found for CTNNB1,
ERBB2, CTSD, KRT19, MMP2, and XBP1 (Fig. 4a).
Next, we focused on ER+ tumors to determine the type of
correlation between ID4 and the specific genes of interest
within this group. By calculation of the correlation coeffi-
cients, we found that ID4 expression is negatively correlated
with the expression of FOXA1 (r =− 0.326) (p < 0.0001),
GATA3 (r = − 0.3515) (p < 0.0001), ESR1 (r = − 0.333)
(p < 0.0001), CCND1(r = − 0.19) (p < 0.0001), AKT1
(− 0.068) (p = 0.094), and IGFR (− 0.065) (p = 0.1) (As
shown in Fig. 4b). These negative correlations main-
tain their significance even when all the tumor co-
horts (ER+ and ER−) are analyzed (Additional file 4:
Figure S4). These results are particularly interesting
given that some authors suggest that ID4 inhibits the
expression of ESR1 and FOXA1 (through the inter-
action of ID4 with the promoter of these genes) in
the developing mammary gland [29]. We hypothesize
then that in an ER+ context, ID4 downregulation,
trough methylation, disrupts the normal balance of
important genes of the ER pathway.
Taken all together, from our in silico analyses, we can
so far propose that in ER+ breast tumors, ID4 behaves
as a tumor suppressor gene epigenetically regulated by
DNA methylation.
Fig. 3 ID4 expression and methylation status in breast cancer using MEXPRESS. At the top of the figure clinical TGCA data available is
represented and ordered according to ID4 expression. At the right-hand side, the Pearson’s correlation coefficient r and the p values for Wilcoxon
rank-sum test are shown. ID4 expression is symbolized as the orange line in the center of the plot. The samples are ordered according to ID4
expression, with the highest expression on the left side and the lowest on the right. The blue lines (bottom right) represent the Infinium 450 k
probes that are linked to ID4. The height of the blue lines indicates the beta value for the probe. The probes localized in the promoter region of
the gene are highlighted in dark blue. ID4 gene and CpG islands (green lines) are represented on the left (bottom)
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Table 1 Genes involved with distinct functions in breast cancer











ADAM23 ADAM metallopeptidase domain 23 Proteolysis
AKT1 AKT serine/threonine kinase 1 Signal transduction (AKT and PI3 kinase signaling)
APC Adenomatosis polyposis coli Signal transduction (WNT signaling), cell adhesion, apoptosis, cell cycle, DNA damage,
and repair
AR Androgen receptor Signal transduction (steroid receptor-mediated signaling) and transcription factor
ATM ATM serine/threonine kinase DNA damage and repair
BCL2 BCL2, apoptosis regulator Signal transduction (hedgehog signaling), cell adhesion, apoptosis, and cell cycle
BIRC5 Baculoviral IAP repeat-containing Signal transduction (Notch signaling)
BRCA1 Breast cancer 1 DNA damage and repair and signal transduction (steroid receptor-mediated signaling)
BRCA2 Breast cancer 2 DNA damage and repair
CCNA1 Cyclin A1 Cell cycle
CCND1 Cyclin D1 Cell cycle, DNA damage and repair, and signal transduction (hedgehog and WNT signaling)
CCND2 Cyclin D2 Cell cycle
CCNE1 Cyclin E1 Cell cycle and signal transduction (steroid receptor-mediated signaling)
CDH13 Cadherin 13 Cell adhesion and angiogenesis
CDK2 Cyclin-dependent kinase 2 Cell cycle
CDKN1A Cyclin-dependent kinase inhibitor 1A Cell cycle, DNA damage and repair, and apoptosis
CDKN1C Cyclin-dependent kinase inhibitor 1AC Cell cycle
CDKN2A Cyclin-dependent kinase inhibitor 2A Cell cycle, apoptosis, and cell adhesion
CST6 Cystatin E/M Proteases
CTNNB1 Catenin beta 1 Signal transduction (steroid receptor-mediated signaling), epithelial to mesenchymal
transition, angiogenesis, and cell adhesion
CTSD Cathepsin D Proteases
EGF Epidermal growth factor Angiogenesis
ERBB2 Erb-b2 receptor tyrosine kinase 2 Signal transduction (AKT/PI3K signaling), angiogenesis, and cell adhesion
ESR1 Estrogen receptor 1 Signal transduction (steroid receptor-mediated signaling) and transcription factor
ESR2 Estrogen receptor 2 Signal transduction (steroid receptor-mediated signaling) and transcription factor
FOXA1 Forkhead box A1 Transcription factor
GATA3 GATA-binding protein 3 Transcription factor
HIC1 HIC ZBTB transcriptional repressor 1 Transcription factor
ID1 Inhibitor of DNA binding 1 Angiogenesis and breast cancer metastasis to lung and breast cancer classification marker
IGF1 Insulin-like growth factor 1 Signal transduction (steroid receptor-mediated and AKT/PI3K signaling)
IGF1R Insulin-like growth factor 1 receptor Signal transduction (AKT/PI3K signaling)
IGFBP3 Insulin-like growth factor-binding protein 3 Signal transduction (glucocorticoid signaling)
IL6 Interleukin 6 Angiogenesis and apoptosis
JUN Jun proto-oncogene Angiogenesis, apoptosis, cell cycle, and transcription factor
KRT19 Keratin 19 Signal transduction (steroid receptor-mediated signaling)
MAPK1 Mitogen-activated protein kinase 1 Signal transduction (MAP kinase-mediated signaling) and DNA damage and repair
MAPK3 Mitogen-activated protein kinase 3 Signal transduction (MAP kinase-mediated signaling)
MAPK8 Mitogen-activated protein kinase 8 Signal transduction (MAP kinase-mediated signaling)
MGMT O-6-methylguanine-DNA methyltransferase DNA damage and repair
MKI67 Marker of proliferation Ki-67 Cell cycle
MLH1 MutL homolog 1 DNA damage and repair
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Ectopic ID4 expression reduces aggressive phenotype
only in ER+ breast cancer cell lines
Based on our in silico conclusions, we decided to extend
our studies and measure tumoral behavior by modulat-
ing the expression of ID4 in cultured ER+ breast cancer
cell lines. To accomplish this, we performed transfection
experiments with an ID4 vector in MCF-7 and T47D
cells. We have previously shown that both cell lines do
not express ID4 due to promoter methylation. [22].
Next, we measured cell migration potential (by wound
healing assays) and colony formation ability, two hall-
marks of cancer cells. As shown in Fig. 5a, both cell lines
transfected with ID4 presented a significant reduction in
migration rate compared to cells transfected with the
control vector (p < 0.05). Consistently, colony formation
assay showed that ID4 overexpression in MCF-7 and
T47D cells led to a significant decrease in the number of
colonies when compared with cells transfected with the
control vector (p < 0.05) (Fig. 5b).
To confirm that ID4 behaves as a tumor suppressor
only in ER+ breast tumors, we tested the effect of ID4
overexpression in the ER− breast cancer cell line
MDA-MB231. To accurately study the effect of ID4 in
an ER− context, we first confirmed by ddPCR that the
MDA-MB231 cell lines did not express ER. Next, we
performed transfection experiments with the ID4 vector
as previously described and tested cell migration poten-
tial (by wound healing assays). ID4 overexpression did
not affect migration capacity of the MDA-MB231 cell
lines (Fig. 6).
Taken together, the transfection assays suggest
concordantly that the ectopic expression of ID4 is
inducing a less aggressive phenotype only in ER+
cell lines, revealed by a decreased migration and a
reduced ability to produce new colonies. These re-
sults are in line with a dual role of ID4 in breast
cancer.
ID4 expression reduces ER levels in MCF-7 cells as
assessed by ddPCR
As we mentioned previously, ID4 expression is associated
with key genes of the ER pathway. Taking this observation
Table 1 Genes involved with distinct functions in breast cancer (Continued)
Gene symbol Gene name Molecular and cellular function
MMP2 Matrix metallopeptidase 2 Proteases and breast cancer metastasis to lung and breast cancer classification marker
MMP9 Matrix metallopeptidase 9 Proteases
MYC V-myc avian myelocytomatosis viral
oncogene homolog
Cell cycle and transcription factor
NME1 NME/NM23 nucleoside diphosphate kinase 1 Signal transduction (glucocorticoid signaling) and apoptosis
NOTCH1 Notch 1 Signal transduction (Notch signaling) and angiogenesis
NR3C1 Nuclear receptor subfamily 3 group C
member 1
Signal transduction (glucocorticoid signaling) and transcription factor
PGR Progesterone receptor Signal transduction (steroid receptor-mediated signaling) and transcription
factor
PLAU Plasminogen activator, urokinase Angiogenesis and proteases
PRDM2 PR/SET domain 2 Transcription factor
PTEN Phosphatase and tensin homolog Signal transduction (AKT/PI3K signaling), angiogenesis, cell adhesion, and cell cycle
PYCARD PYD and CARD domain-containing Proteases
RARB Retinoic acid receptor beta Apoptosis and transcription factor
RASSF1 Ras-association domain family member 1 Cell cycle
RB1 RB transcriptional corepressor 1 Signal transduction (steroid receptor-mediated signaling), cell cycle,
and transcription factor
SERPINE1 Serpin family E member 1 Angiogenesis
SFN Stratifin Apoptosis, cell cycle, and DNA damage and repair
SFRP1 Secreted frizzled-related protein Signal transduction (WNT signaling) and apoptosis
SLIT2 Slit guidance ligand 2 Angiogenesis
THBS1 Thrombospondin 1 Angiogenesis and cell adhesion
TP53 Tumor protein p53 Apoptosis, cell cycle, DNA damage and repair, and transcription factor
TP73 Tumor protein p73 Apoptosis, DNA damage and repair, transcription factor, and signal transduction
(MAP kinase signaling)
VEGFA Vascular endothelial growth factor Angiogenesis
XBP1 X-box binding protein 1 Transcription factor
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into consideration, we decided to study the effect of ID4
overexpression on ER levels in an ER+ cell line. To test
this, we transfected MCF-7 cells with the ID4-expressing
plasmid. As control, cells were transfected with the GFP
control vector. When obtaining total RNA from both ex-
periments and measuring the expression level of ER by
ddPCR, a significant difference could be observed. As
shown in Fig. 7, ID4 overexpression induced a significant
reduction in ER levels of MCF-7 cells as compared to the
same cells transfected with a control vector (p < 0.01).
Given that in ER+ breast, tumors ER levels are
higher than in normal tissue, and these higher levels
are associated with certain aggressive characteristics
































































































































































Fig. 4 Genes associated with ID4 expression. a Venn diagram representing the expression for genes significantly associated with the expression
of ID4 in breast cancer as determined by SVD analysis. The figure depicts the genes significantly associated with ID4 in ER+ and ER− tumors and
the overlap the genes with shared expression between the two groups. b Correlations between ID4 expression and the expression of FOXA1,
ESR1, GATA3, CCND1, AKT, and IGF1R. Correlation values for each analysis are indicated on the right
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that ID4 re-expression in ER+ cell lines reduces the
ER levels perhaps to those of normal tissue and pos-
sibly exerts its tumor suppressor function trough ER
regulation (Fig. 7).
ER levels do not affect methylation nor ID4 expression
levels in MCF-7 cell lines
To study if there is a regulatory loop between ER and ID4,
we next tested if estrogen deprivation affected the methy-
lation status or the expression levels of ID4 in the ER+ cell
line MCF-7. To test this, we first treated the cells with
1μM of the ER antagonist fulvestrant and measured ID4
methylation status by ddMSP and MS-MLPA. As shown
in Fig. 8a, there was a slight reduction in the methylation
levels of fulvestrant treated cells, but this difference was
not statically significant (p = 0.45). To further analyze if
there were changes in the methylation status of other re-
gions of ID4 promoter, we performed a MS-MLPA assay
with the ME003 panel. This panel contains 27 probes two
of which hybridize at different CpG sites from that tested
by ddMSP. The MS-MLPA assay revealed that there was
no significant difference in the methylation level between
control and fulvestrant-treated cells in neither of the CpG
sites tested (Additional file 5: Figure S5).
Since it has been shown that promoter methylation is
the main mechanism that controls ID4 gene expression
[13, 17, 28], we speculated (given our ddMSP and
MS-MLPA results) that there was not going to be differ-
ences in ID4 gene expression after estrogen deprivation.
To confirm this, we performed in silico analysis on a
public data set of an in vitro model of MCF-7 cells


















































































































Fig. 5 Phenotypic changes associated with ectopic ID4 expression in breast cancer cell lines. a Bar graph presentation of wound healing assay
comparisons. The effect of ectopic expression of ID4 was tested on cell migration ability in MCF-7 and T47D cell lines (left and right respectively).
Columns represent the mean of at least three independent experiments. *p < 0.05 and **p < 0.01 in comparison with the control per Student’s t
test. For migration experiments, cells were maintained in a serum-reduced medium to inhibit the cells’ ability to proliferate. b Colony formation
assay was used to confirm the effect of ID4 expression in T47D and MCF-7 transfected either with ID4 or the control vector. Results are expressed
as the mean ± SD of three independent experiments
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(ArrayExpress accession number E-MTAB-4426), and as
shown in Fig. 8b, there were no differences on ID4 gene
expression between control and fulvestrant-treated cells.
Taken together, our results reveal that while ID4 reduces
ER expression, estrogen levels do not affect neither ID4
methylation nor ID4 expression. These observations sug-
gest that there seems not to be a regulation of estrogen to-
wards ID4.
Discussion
Given a certain cellular context, ID proteins may follow
divergent functions and act as tumor suppressors or as on-
cogenes [2]. Particularly, ID4 can act as a tumor
suppressor and as an oncogene in different tumor types,
e.g., prostate, gastric, glioblastomas, and colorectal tumors
[1, 11, 13, 28–30]. In breast cancer, our group and others
have previously shown that ID4 may behave as an onco-
gene in TNBC or basal-like breast tumors. Principally in
ER− tumors, the role of ID4 has been linked to BRCA1
downregulation and BRCAness phenotype [21, 22, 31].
But other authors have shown that ID4 may also act as a
tumors suppressor in breast cancer [17, 32], where there
a
Fig. 6 ID4 overexpression does not affect migration capacity in the ER
− cell line MDA-MB231. The effect of ectopic expression of ID4 was
tested on cell migration ability in the MDA-MB231 cell line. Columns
represent the mean of at least three independent experiments
a b
Fig. 7 ID4 re-expression reduces ERα levels in MCF-7 cell lines. The figure represents the absolute quantification of ER expression (top left) and
normalized respect to β-actin (right) by ddPCR. The fluorescence amplitude (y-axis) represents the intensity of amplification in each droplet, and
each blue dot is a droplet in which the target has been amplified. To calculate the copies/droplet, a Poisson correction is performed which
requires full (dost above the pink line) and empty droplets (dots below the horizontal pink line). For this, a minimum and equal amount of
template cDNA (10 ng) is used for each condition. a With the ddPCR assay for ER expression, a variation was observed in the number of droplets
with signal of ERα detection. β-actin was used as a control. Results are presented as copies per microliter in the amplification reaction. b Bar
graph represents the mean of three technical experiments measuring the expression of ER in ID4-transformed MCF7 cells, by ddPCR. **p < 0.05
in comparison with the control per Student’s t test
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seem to be controversial findings regarding the role of
ID4. We hypothesize that ID4 behaves as both a tumor
suppressor and an oncogene as well and that the differ-
ence in behavior varies according to the ER status of
breast tumors.
In this report, we used two approaches to test our
hypothesis: data mining analysis and in vitro experi-
ments. Data mining analysis revealed that ID4 expres-
sion is significantly downregulated in ER+ breast
tumors as compared with ER− tumors or normal tis-
sue. We show here that ID4 is silenced in breast tu-
mors through promoter methylation and that ID4 is
methylated as tumors become ER+. Interestingly, ID4
expression is significantly higher in normal tissue with
respect to breast tumors either they are ER+ or ER−.
This could be indicating that ID4 expression is re-
quired for normal mammary function and that during
a tumorigenic process (either ER+ or ER−), ID4’s ex-
pression is reduced through methylation. Comparing
ER+ with ER− tumors, the methylation levels are not
the same. Therefore, there are different expression
levels of ID4 between these tumor types and possibly
different pathways are turned on or off according to
differences in ID4 expression. Some authors suggest
that ID4 regulates linage commitment and forms part
of a complex regulatory network with ERα and BRCA1
in the normal mammary gland [18]. Perhaps during
mammary tumorigenesis, ID4 follows divergent pathways
in ER+ and ER− tumors, affecting different cellular net-
works. Previously published work shows that specific
binding of ID4 (as part of a larger complex) occurs at a re-
gion located 5.9 kb upstream of the ERα promoter [29].
Here, we show that ID4 re-expression in MCF-7 cells in-
duced a significant reduction in ER α expression. We also
demonstrate by in silico analysis that ID4 expression is as-
sociated with different genes according to ER status. In ER
+ tumors, ID4 expression was negatively correlated to the
expression of key genes of the ER pathway such as
FOXA1, GATA3, ESR1, and CCND1. Interestingly, all the
four genes are involved in the ER pathway. An ID4 site
has been identified 8.3 kb upstream of the FOXA1 tran-
scription start site and perhaps forms part of a similar
protein complex [29]. Taking these observations into con-
sideration, we could speculate that in the normal mam-
mary gland, ID4 is an important member of the ER
pathway and when its expression is affected by methyla-
tion, and in ER+ tumors, the expression of important
players of the ER pathway is disturbed.
a
b
Fig. 8 Estrogen deprivation does not affect neither ID4 methylation nor ID4 expression. a Left, ddPCR assay for the detection of ID4-methylated
status in control and fulvestrant-treated MCF-7 cells. Results are presented as copies per microliter in the amplification reaction. Right, bar graph
represents the mean of three technical experiments measuring the methylated/unmethylated ratios of the control and experimental conditions.
b ID4 probe (A_23_P59375) intensity was compared between control and fulvestrant-treated MCF-7 cells
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The observation that the expression of ID4 associates
with VEGF, JUN, and MKI67 in ER− tumors has not been
previously described in breast cancer and it reveals that
the involved pathways differ depending on the ER status.
We also evaluated the effect of ID4 expression on OS
in breast cancer patients. We observed that in ER+
breast tumors, high ID4 expression was associated with
better probabilities of survival. This was not observed
among ER− tumors, where the expression of ID4 does
not correlate with OS. It is worth mentioning, however,
that in the basal-like subgroup of ER− tumors, the expres-
sion of ID4 did show a positive association with worst sur-
vival (p = 0,043). Even though we do not yet understand
why this subgroup presents this behavior, it supports the
hypothesis of a dual role for ID4 based on the ER status.
Finally, the putative tumor suppressor function of
ID4 in ER+ breast cancer was verified by in vitro assays.
ID4 overexpression induced phenotypic changes associ-
ated with a tumor suppressor role for this protein in ER
+ breast cancer cell lines. This was evidenced by re-
duced migration rates in both breast cancer cell lines
analyzed. The reduction in migration could be related
to the fact that we found ID4 associated with CCND1,
which regulates migration and proliferation in breast
cancer cells [33–35]; perhaps, these changes in migra-
tion are due to an interaction between ID4 and
CCND1. This would not be the first case reporting an
association between a member of the ID family with
CCND1. For instance, Tobin et al. established that
there exists a relationship between cyclin D1, ID1, and
EMT in primary breast cancer [36]. Ours is the first re-
port suggesting an association between ID4 and
CCND1 in breast cancer. Further research should be
conducted to confirm this data. Our observations that
ectopic expression of ID4 also leads to a significant de-
crease in the number of colonies is also in line with a
tumor suppressor role for this protein.
Conclusions
We propose that ID4 is frequently silenced by promoter
methylation in ER+ breast cancers and functions as a
tumor suppressor gene in these tumors, probably be-
cause of its negative interaction with key genes of the ER
pathway. Our present study contributes to the know-
ledge of the role of ID4 in breast cancer.
Additional files
Additional file 1: Figure S1. qPCR and Western blot analysis of ID4
expression in control and transfected cells with ID4. (AI 1152 kb)
Additional file 2: Figure S2. Higher ID4 expression is associated with
OS in ER+ tumors. Kaplan–Meier analysis of the Miller 2005 cohort
evaluating OS in ER+ tumors. (AI 1076 kb)
Additional file 3: Figure S3. ID4 methylation values according to ER
status. Box plot representation of β values of ID4 methylation at different
sites in ID4 promoter. The bottom and top of the box represent the first
and third quartiles of the data, respectively, and the band inside the box
represents the median of the data. The lower and upper whiskers
represent the lowest and highest data points of the data, respectively.
***p < 0.001. (AI 1193 kb)
Additional file 4: Figure S4. Genes associated with ID4 expression in
ER+ and ER− tumors. Correlations between ID4 expression and the
expression of FOXA1, ESR1, GATA3, CCND1, AKT, and IGF1R in the
complete tumor cohort (ER+ and ER−). Correlation values for each
analysis are indicates on the right. (AI 1561 kb)
Additional file 5: Figure S5. MS-MLPA analysis of ID4 status after
fulvestrant treatment. MS-MLPA ME003 probemix was used to analyze
ID4 status after estrogen deprivation in MCF7 cells. (AI 1416 kb)
Abbreviations
bHLH: Basic helix-loop-helix; ER: Estrogen receptor; ID: Inhibitor of
differentiation; KM: Kaplan–Meier; OS: Overall survival; SVD: Singular-value
decomposition; TCGA: The Cancer Genome Atlas
Funding
This work was supported in part by grants from the National Council for Scientific
and Technical Research (CONICET, grant number PIP 112–201301-00693) and by
the National Institute of Cancer (“Instituto Nacional del Cancer”), Argentina.
Availability of data and materials
The datasets analyzed during the current study are available in UCSC Xena at
http://xena.ucsc.edu/, in Kaplan Meier Plotter at http://kmplot.com/analysis/, and
in MEXPRESS at http://mexpress.be/. For estrogen deprivation analysis, microarray
data was obtained from Array-Express accession number E-MTAB-4426.
Authors’ contributions
DN performed in vitro experiments, i.e., cellular transfection, and migration
assays. EC performed cellular transfection, migration, and colony formation
assays. SL and DN participated in droplet digital PCR experiments. RB
performed computational and statistical analysis and revised the final
manuscript. GU assisted in migration assays. MR made substantial
contributions to the conception and design of the experiments and the
manuscript. MTB conceived the study, participated in its design, and wrote
the manuscript. All authors read and approved the final manuscript.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1IHEM, National University of Cuyo, CONICET, Mendoza, Argentina. 2IHEM,
Faculty of Exact and Natural Sciences, National University of Cuyo, CONICET,
Mendoza, Argentina. 3IHEM, CONICET, Facultad de Ciencias Médicas, National
University of Cuyo, Mendoza, Argentina. 4IANIGLA, CONICET, Mendoza,
Argentina.
Received: 22 December 2017 Accepted: 6 August 2018
References
1. Patel D, Morton DJ, Carey J, Havrda MC, Chaudhary J. Inhibitor of
differentiation 4 (ID4): from development to cancer. Biochim Biophys Acta
Rev Cancer. 2015;1855:92–103.
Nasif et al. Clinical Epigenetics  (2018) 10:111 Page 13 of 14
2. Lasorella A, Benezra R, Iavarone A. The ID proteins: master regulators of cancer
stem cells and tumour aggressiveness. Nat Rev Cancer. 2014;14:77–91.
3. Fontemaggi G, Dell’Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, et al.
The execution of the transcriptional axis mutant p53, E2F1 and ID4
promotes tumor neoangiogenesis. Nat Struct Mol Biol [Internet].2009;
16:1086–93.
4. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development
and cancer. Oncogene [Internet]. 2001;20:8326–33.
5. Bedford L, Walker R, Kondo T, Van Crüchten I, King ER, Sablitzky F. Id4 is
required for the correct timing of neural differentiation. Dev Biol. 2005;280:
386–95.
6. Tokuzawa Y, Yagi K, Yamashita Y, Nakachi Y, Nikaido I, Bono H, et al. Id4, a
new candidate gene for senile osteoporosis, acts as a molecular switch
promoting osteoblast differentiation. PLoS Genet. 2010;6:1–15.
7. Murad JM, Place CS, Ran C, SKN H, Watson NP, Kauppinen RA, et al. Inhibitor
of DNA binding 4 (ID4) regulation of adipocyte differentiation and adipose
tissue formation in mice. J Biol Chem. 2010;285:24164–73. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2911309&tool=
pmcentrez&rendertype=abstract.
8. Sharma P, Knowell AE, Chinaranagari S, Komaragiri S, Nagappan P, Patel D,
et al. Id4 deficiency attenuates prostate development and promotes PIN-like
lesions by regulating androgen receptor activity and expression of NKX3.1
and PTEN. Mol Cancer. 2013;12:67. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3694449&tool=
pmcentrez&rendertype=abstract.
9. Chaudhary J, Johnson J, Kim G, Skinner MK. Hormonal regulation and
differential actions of the helix-loop-helix transcriptional inhibitors of
differentiation (Id1, Id2, Id3, and Id4) in Sertoli cells. Endocrinology. 2001;
142:1727–36.
10. Dong J, Huang S, Caikovski M, Ji S, McGrath A, Custorio MG, et al. ID4
regulates mammary gland development by suppressing p38MAPK activity.
Development. 2011;138:5247–56.
11. Vinarskaja A, Goering W, Ingenwerth M, Schulz WA. ID4 is frequently
downregulated and partially hypermethylated in prostate cancer. World J
Urol. 2012;30:319–25.
12. Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S, et al.
Multiplexed methylation profiles of tumor suppressor genes and clinical
outcome in lung cancer. J Transl Med. 2010;8:86.
13. Chan ASW, Tsui WY, Chen X, Chu KM, Chan TL, Chan ASY, et al.
Downregulation of ID4 by promoter hypermethylation in gastric
adenocarcinoma. Oncogene. 2003;22:6946–53.
14. Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, et al.
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the
ovarian cancer oncogene ID4. Sci Transl Med. 2012;4:147ra112. Available
from: http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.3003778.
15. Martini M, Cenci T, D’Alessandris GQ, Cesarini V, Cocomazzi A, Ricci-Vitiani L,
et al. Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a
better prognosis as a consequence of an inhibition of angiogenesis. Cancer.
2013;119:1004–12.
16. Verschuur-Maes AHJ, De Bruin PC, Van Diest PJ. Epigenetic progression of
columnar cell lesions of the breast to invasive breast cancer. Breast Cancer
Res Treat. 2012;136:705–15.
17. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, et al.
Promoter methylation-associated loss of ID4 expression is a marker of
tumour recurrence in human breast cancer. BMC Cancer. 2008;8:154.
18. Junankar S, Baker LA, Roden DL, Nair R, Elsworth B, Gallego-Ortega D, et al.
ID4 controls mammary stem cells and marks breast cancers with a stem
cell-like phenotype. Nat Commun. 2015;6:6548. Available from: http://www.
nature.com/doifinder/10.1038/ncomms7548.
19. Branham MT, Marzese DM, Laurito SR, Gago FE, Orozco JI, Tello OM, et al.
Methylation profile of triple-negative breast carcinomas. Oncogene. 2012;1:e17.
20. Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welcsh P, et al.
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-
library-based inverse genomics approach. Proc Natl Acad Sci U S A.
2001;98:130–5.
21. Wen YH, Ho A, Patil S, Akram M, Catalano J, Eaton A, et al. Id4 protein is
highly expressed in triple-negative breast carcinomas: possible implications
for BRCA1 downregulation. Breast Cancer Res Treat. 2012;135:93–102.
22. Branham MT, Campoy E, Laurito S, Branham R, Urrutia G, Orozco J, et al.
Epigenetic regulation of ID4 in the determination of the BRCAness
phenotype in breast cancer. Breast Cancer Res Treat. 2016;155:13–23.
23. Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ, Hoon DSB.
Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor
differentiation and unfavorable prognosis. Clin Cancer Res. 2004;10:7475–83.
24. Koch A, De Meyer T, Jeschke J, Van Criekinge W. MEXPRESS: visualizing
expression, DNA methylation and clinical TCGA data. BMC Genomics. 2015;
16:636. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26306699.
25. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online
survival analysis tool to rapidly assess the effect of 22,277 genes on breast
cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res
Treat. 2010;155:725–31.
26. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An
expression signature for p53 status in human breast cancer predicts
mutation status, transcriptional effects, and patient survival. Proc Natl Acad
Sci. U S A. 2005;102:13550–5. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/16141321, http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid=PMC1197273.
27. Thewes V, Simon R, Hlevnjak M, Schlotter M, Schroeter P, Schmidt K, et al. The
branched-chain amino acid transaminase 1 sustains growth of antiestrogen-
resistant and ERα-negative breast cancer. Oncogene. 2017;36:4124–34.
Available from: http://www.nature.com/doifinder/10.1038/onc.2017.32.
28. Hagiwara K, Nagai H, Li Y, Ohashi H, Hotta T, Saito H. Frequent DNA
methylation but not mutation of the ID4 gene in malignant lymphoma.
J Clin Exp Hematop. 2007;47:15–8.
29. Best SA, Hutt KJ, Fu NY, Vaillant F, Liew SH, Hartley L, et al. Dual roles for Id4
in the regulation of estrogen signaling in the mammary gland and ovary.
Development. 2014;141:3159–64. Available from: http://dev.biologists.org/
content/141/16/3159.full.
30. Rahme GJ, Israel MA. Id4 suppresses MMP2-mediated invasion of
glioblastoma-derived cells by direct inactivation of Twist1 function.
Oncogene. 2015;34:53–62. Available from: http://www.nature.com/doifinder/
10.1038/onc.2013.531.
31. Crippa E, Lusa L, De Cecco L, Marchesi E, Calin GA, Radice P, et al. miR-342
regulates BRCA1 expression through modulation of ID4 in breast cancer.
PLoS One. 2014;9:e87039.
32. Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE, et al.
Aberrant hypermethylation of ID4 gene promoter region increases risk of
lymph node metastasis in T1 breast cancer. Oncogene. 2005;24:4721–7.
33. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, et al. Cyclin D1
and prognosis in human breast cancer. Int J Cancer. 1996;69:92–9. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/8608989.
34. Yang C, Chen L, Li C, Lynch MC, Brisken C, Schmidt EV. Cyclin D1 enhances
the response to estrogen and progesterone by regulating progesterone
receptor expression. Mol Cell Biol. 2010;30:3111–25. Available from: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2876668&tool=
pmcentrez&rendertype=abstract.
35. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast. 2006;15:718–27.
36. Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G. Cyclin D1, Id1 and
EMT in breast cancer. BMC Cancer. 2011;11:417. Available from: http://
bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-417.
Nasif et al. Clinical Epigenetics  (2018) 10:111 Page 14 of 14
